News 2010
Below, please find a list of all LEO news from 2010.
Press releases
30-05-2010
LEO Pharma in dialogue with Greek authorities on alternative to withdrawing products
LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company’s pharmaceutical products from the Greek market.
24-03-2010
LEO Pharma’s 2009 financial statements reflect extensive investments in the future
LEO Pharma’s 2009 financial statements testify to considerable investments in the company’s future with the establishment of new sales units, the acquisition of a biotech company and the reacquisition of the company’s rights to market LEO products in the US.
05-03-2010
Phase III REGION-I Study Shows PEP005 (ingenol mebutate) Gel 0.05% May Reduce Pre-Cancerous Skin Lesions in Patients with Actinic Keratosis
Data Presented at the 68th Annual Meeting of the American Academy of Dermatology. Specialty pharmaceutical company LEO Pharma today announced that findings from a Phase III study evaluating PEP005 (ingenol mebutate) Gel 0.05% to treat actinic keratosis (AK), a common pre-cursor to skin cancer, were presented at the 68th Annual Meeting of the American Academy of Dermatology (AAD) (Scientific Session Poster Discussion: P105).
01-02-2010
LEO Pharma’s PEP005 Meets Primary Endpoint in Phase III Trial for Pre...
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company’s lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations. Findings from the REGION Ib study in body AK support results from the earlier REGION-I trial, a study evaluating PEP005 for the treatment of AK on the head reported in December 2009.
